Evidence map›Paper›PMID 32178642›Full record

ArticleBMC cancer2020

P16 as a marker of carcinoma in effusions and peritoneal washing.

Fabiana Pirani Carneiro, Rivadávio Fernandes Amorim, Marcos de Vasconcelos Carneiro, Tercia Maria Mendes Lousa de Castro, Leonora Maciel de Souza Vianna, Gustavo Henrique Soares Takano, Andersen Charles Daros, Isabela Peres, Selma Aparecida Souza Kuckelhaus, Andrea Barretto Motoyama

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Fabiana Pirani CarneiroPathological Anatomy Center of University Hospital of Brasilia, Via L2 Norte, SGAN 604/605, Brasília DF, 70840-050, Brazil. fabianapirani@hotmail.com.
Rivadávio Fernandes AmorimPathology Department of Brasília University, Brasília, Brazil.
Marcos de Vasconcelos CarneiroCatholic University of Brasilia, Brasília, Brazil.
Tercia Maria Mendes Lousa de CastroPathology Department of Brasília University, Brasília, Brazil.
Leonora Maciel de Souza ViannaPathological Anatomy Center of University Hospital of Brasilia, Via L2 Norte, SGAN 604/605, Brasília DF, 70840-050, Brazil.
Gustavo Henrique Soares TakanoPathological Anatomy Center of University Hospital of Brasilia, Via L2 Norte, SGAN 604/605, Brasília DF, 70840-050, Brazil.
Andersen Charles DarosPathology Department of Brasília University, Brasília, Brazil.
Isabela PeresPathological Anatomy Center of University Hospital of Brasilia, Via L2 Norte, SGAN 604/605, Brasília DF, 70840-050, Brazil.
Selma Aparecida Souza KuckelhausMorphology Department of Brasília University, Brasília, Brazil.
Andrea Barretto MotoyamaPathology Department of Brasília University, Brasília, Brazil.
Hospital Universitário de Brasília · BRUniversidade de Brasília · BRUniversidade Católica de Brasília · BR

Funding

Fundação de apoio à pesquisa do DF (FAP-DF), FAHUB, CAPES CNPQ and Fundação de Ensino e Pesquisa em Ciências da Saúde (FEPECS). 0
6 · The paper itself

Abstract

backgroundConsidering the potential of p16 as a marker for diagnosis, prognosis and therapeutic response, the aim of this study was to assess its presence, via immunocytochemistry, in metastatic carcinoma of different primary sites and histological types obtained from effusions and peritoneal washings. A total of 118 samples including 85 of metastatic carcinoma and 33 samples of benign effusion/peritoneal washing were prepared by the plasma/thromboplastin method. Immunocytochemistry reactions were performed on cell block sections using antibodies against p16, claudin-4, MOC-31, calretinin, HBME and CD68.

resultsP16 overexpression was observed in 88.23% of all carcinoma samples. All cervix adenocarcinoma samples showed p16 overexpression. Overexpression in adenocarcinomas of ovary, lung and breast was observed in 93.75, 93.10 and 75% of the samples, respectively. Overexpression was observed in all different histological types analyzed: small cell carcinoma (lung), squamous cell carcinoma (cervical) and urothelial carcinoma (bladder). The specificity of p16 for carcinoma detection was of 96.96%.

conclusionOverexpression of p16 was observed in most metastatic carcinoma, from different primary sites and histological types, obtained from effusions and peritoneal washings. Due to its high frequency of overexpression in metastatic carcinoma, p16 may play a possible role in tumor progression and it may be considered as a complementary diagnostic marker depending on histological type and primary site of carcinoma.

Indexed as

Antigens, CDAntigens, Differentiation, MyelomonocyticAntigens, SurfaceAscitic FluidBiomarkers, TumorCalbindin 2CarcinomaCD68 MoleculeClaudin-4Cyclin-Dependent Kinase Inhibitor p16Epithelial Cell Adhesion MoleculeHumansNeoplasmsPericardial EffusionPleural Effusion, MalignantPrognosisAntigens, CDAntigens, Differentiation, MyelomonocyticAntigens, SurfaceBiomarkers, TumorCalbindin 2CD68 antigen, humanCD68 MoleculeCDKN2A protein, humanClaudin-4Cyclin-Dependent Kinase Inhibitor p16EPCAM protein, humanEpithelial Cell Adhesion MoleculeCarcinomaCytologyImmunocytochemistryp16, effusion

Identifiers

PMID32178642
PMCPMC7076945
OpenAlexW3012160423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.